Tedd Van Buskirk’s commitment to client service and dedication to thoroughness has led to success over the course of his 20-year career. Tedd is an intellectual property attorney with a life sciences focus and serves clients in the pharmaceutical, medical device, and biotechnology industries. Tedd co-leads the firm's Hatch-Waxman Litigation practice.
Tedd has extensive experience litigating patent and trademarks, trade secrets, unfair competition, and related antitrust issues. During his career, Tedd's practice has encompassed a variety of technologies, including medical devices, pharmaceuticals, nutraceuticals and supplements, drug delivery devices, foods, chemicals, biologics, consumer products, toys, telecommunications, computer hardware and software, and electronics. He has appeared in tribunals across the nation in all phases of litigation – from filing through trial.
Tedd has litigated and arbitrated dozens of patent cases involving both branded and generic drugs, active pharmaceutical ingredients, food ingredients and supplements, enzymes, gastric bands, breast implants, tissue expanders, livestock technology, and consumer products, among others. He has significant experience counseling clients in and litigating Abbreviated New Drug Application (ANDA) cases arising out of the complex intersection of the patent and FDA laws relating to the Hatch-Waxman amendments to the Federal Food, Drug & Cosmetic Act.
In addition to his litigation practice, Tedd is a registered patent attorney who prepares and prosecutes patent and trademark applications and has handled patent interferences, post grant proceedings, and trademark oppositions. He frequently delivers opinions on the scope, validity, and enforceability of patents. He also counsels established and emerging companies, venture capital and private equity firms, and underwriters in intellectual property licensing and transactional matters.
Tedd is a frequent panelist and speaker at the American Conference Institute's Hatch-Waxman series of events and has published and been quoted in the press on issues affecting the pharmaceutical industry.